Wei Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wei Sun has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Lingli Dong
Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 shared publications - Shaozhe Cai
Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
3 shared publications Chengqian Liao
Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
2 shared publicationsChenyang Zhang
Department of Stomatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China; School of Stomatology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
1 shared publicationCong Ye
Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
1 shared publication- Guangjin Chen
Hospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, 510055, China
1 shared publication
Latest Publications
- Open Access
- 17 July 2026
- Published by Elsevier in Pharmacological Research
- Vol. 231, 108346
Acetyl-CoA metabolism in skeletal biology and bone disorders: From mechanisms to therapeutic implications
- 17 July 2026
- Published by Elsevier in Pharmacological Research
- Vol. 231, 108346
Open AccessAcetyl-CoA metabolism in skeletal biology and bone disorders: From mechanisms to therapeutic implications
- 8 June 2026
- Published by Springer Nature in Inflammation Research
- Vol. 75 (1)
Targeting FcRn for immunomodulation: a promising therapy in autoimmune inflammatory rheumatic diseases
Autoimmune inflammatory rheumatic diseases (AIIRD) are systemic disorders characterized by breakdown of immune tolerance and production of pathogenic IgG autoantibodies, leading to chronic inflammation and tissue damage. The rapid and selective lowering of pathogenic IgG therefore has therapeutic appeal. The neonatal Fc receptor (FcRn) is a key regulator of IgG homeostasis, which mediates the IgG half-life extension and transportation across cell barriers, while also facilitating antigen presentation. Targeting FcRn offers a novel, precision medicine approach to reduce pathogenic IgG burden and regulate immunity without inducing broad immunosuppression. This review summarizes FcRn biology, discusses the therapeutic rationale for FcRn inhibition, maps the evolving pipeline of FcRn inhibitors, and integrates key preclinical and clinical evidence across rheumatic indications. It also addresses practical considerations for clinical implementation and pharmacoeconomics, together with future directions for the field. FcRn inhibition accelerates IgG catabolism and potentially dampens downstream inflammatory circuits by reducing immune-complex-mediated activation and related immune signaling. This rationale is supported by multiple preclinical models and emerging clinical data. Several FcRn-targeted agents, including efgartigimod, nipocalimab, and IMVT-1402, are currently in clinical development for various indications encompassing idiopathic inflammatory myopathies (IIM), Sjögren's disease (SjD), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). FcRn blockade represents a promising precision-medicine strategy for IgG-driven AIIRD. Future studies should define optimal patient populations, identify predictive biomarkers, optimize next-generation molecules, and clarify long-term safety, pharmacoeconomic value, and opportunities for indication expansion.
- 8 June 2026
- Published by Springer Nature in Inflammation Research
- Vol. 75 (1)
Targeting FcRn for immunomodulation: a promising therapy in autoimmune inflammatory rheumatic diseases
Autoimmune inflammatory rheumatic diseases (AIIRD) are systemic disorders characterized by breakdown of immune tolerance and production of pathogenic IgG autoantibodies, leading to chronic inflammation and tissue damage. The rapid and selective lowering of pathogenic IgG therefore has therapeutic appeal. The neonatal Fc receptor (FcRn) is a key regulator of IgG homeostasis, which mediates the IgG half-life extension and transportation across cell barriers, while also facilitating antigen presentation. Targeting FcRn offers a novel, precision medicine approach to reduce pathogenic IgG burden and regulate immunity without inducing broad immunosuppression. This review summarizes FcRn biology, discusses the therapeutic rationale for FcRn inhibition, maps the evolving pipeline of FcRn inhibitors, and integrates key preclinical and clinical evidence across rheumatic indications. It also addresses practical considerations for clinical implementation and pharmacoeconomics, together with future directions for the field. FcRn inhibition accelerates IgG catabolism and potentially dampens downstream inflammatory circuits by reducing immune-complex-mediated activation and related immune signaling. This rationale is supported by multiple preclinical models and emerging clinical data. Several FcRn-targeted agents, including efgartigimod, nipocalimab, and IMVT-1402, are currently in clinical development for various indications encompassing idiopathic inflammatory myopathies (IIM), Sjögren's disease (SjD), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). FcRn blockade represents a promising precision-medicine strategy for IgG-driven AIIRD. Future studies should define optimal patient populations, identify predictive biomarkers, optimize next-generation molecules, and clarify long-term safety, pharmacoeconomic value, and opportunities for indication expansion.
- 26 March 2026
- Published by Elsevier in Autoimmunity Reviews
- Vol. 25 (5) , 104042
The BAFF/APRIL system at the crossroads of B cell memory and autoimmune relapse: Implication into the therapeutic strategies
- 26 March 2026
- Published by Elsevier in Autoimmunity Reviews
- Vol. 25 (5) , 104042
The BAFF/APRIL system at the crossroads of B cell memory and autoimmune relapse: Implication into the therapeutic strategies
- Open Access
- 29 January 2026
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 28 (1)
Reassessing the role of watchful waiting strategy for IgG4-related disease: a real-world study
To investigate the feasibility and potential efficacy of “watchful waiting” strategy in IgG4-related disease (IgG4-RD) patients being asymptoma
- 29 January 2026
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 28 (1)
Open AccessReassessing the role of watchful waiting strategy for IgG4-related disease: a real-world study
To investigate the feasibility and potential efficacy of “watchful waiting” strategy in IgG4-related disease (IgG4-RD) patients being asymptoma